This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
BD (BDX) Veritor At-Home COVID-19 Test Receives EUA From FDA
by Zacks Equity Research
EUA for BD's (BDX) At-Home COVID-19 test is expected to boost home testing to prevent outbreaks and limit the rise in COVID-19 cases from the Delta variant.
Here's Why You Should Retain BD (BDX) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about BD (BDX) owing to its slew of product launches and regulatory approvals.
Walgreens (WBA) Provides Flu Shots Nationwide for Ages 3 & More
by Zacks Equity Research
Walgreens (WBA) is ready to co-administer COVID-19 vaccines and flu shots anticipating COVID-19 boosters in September.
HSIC vs. CNMD: Which Stock Is the Better Value Option?
by Zacks Equity Research
HSIC vs. CNMD: Which Stock Is the Better Value Option?
Omnicell (OMCL) Enhances Medication Management With New Release
by Zacks Equity Research
Omnicell's (OMCL) Summer 2021 Release offers greater platform deployment options, providing customers better flexibility and improving time to value for strategic initiatives.
Align Technology (ALGN) at a 52-Week High: What's Driving It?
by Zacks Equity Research
Strong performance by the Clear Aligners and Systems & CAD/CAM Services segments drove the top line for Align Technology (ALGN).
Abbott's (ABT) Base Volume Rebounds, Lowered View Concerns
by Zacks Equity Research
Abbott's (ABT) Diabetes Care business has been in the limelight for developments in its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
Here's Why You Should Retain Patterson Companies (PDCO) Stock
by Zacks Equity Research
Patterson Companies (PDCO) continues to benefit from strength in Animal Health business and dental business. However, high debt level remains a woe.
Quest Diagnostics (DGX) Acquires Florida-Based NLS Assets
by Zacks Equity Research
Quest Diagnostics (DGX) expects the acquisition to broaden the company's spectrum in diagnostic innovation and insights.
Here's Why You Should Retain Masimo (MASI) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Masimo (MASI) owing to its slew of product launches and regulatory approvals.
Here's Why You Should Hold on to Thermo Fisher (TMO) for Now
by Zacks Equity Research
Investors are optimistic about Thermo Fisher (TMO) on robust segmental growth and raised 2021 guidance.
Here's Why You Should Hold on to NextGen (NXGN) Stock Now
by Zacks Equity Research
NextGen (NXGN) continues to gain momentum on the back of solid demand for its solutions and strength in EHR. However, intense competition woes linger.
Masimo's (MASI) Noninvasive Continuous PVi Favored by New Study
by Zacks Equity Research
Masimo (MASI) reports study findings that will aid clinicians in getting meaningful information with respect to monitoring the volume status in critically ill patients with spontaneous breathing.
Here's Why You Should Retain PacBio (PACB) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about PacBio (PACB) owing to its slew of strategic deals and strength in its Sequel system.
Intersect ENT's (XENT) Sell Off Plan Strategic Amid Pandemic
by Zacks Equity Research
Intersect ENT's (XENT) top-line growth from the PROPEL family of products and SINUVA continues to be challenged by seasonal variations in the volume of sinus surgery procedures.
Bruker (BRKR) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Bruker (BRKR) on solid BSI Nano Group growth potential and raised 2021 financial guidance.
Here's Why You Should Invest in West Pharmaceutical (WST) Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum on the back of strength in Proprietary Products business.
Illumina (ILMN) Shares Slip on GRAIL Buyout Deal Completion
by Zacks Equity Research
Illumina (ILMN) acquisition of GRAIL will expand patient access to life-saving multi-cancer early-detection test.
Here's Why You Should Add IDEXX (IDXX) to Your Portfolio Now
by Zacks Equity Research
Investors are optimistic about IDEXX (IDXX) on strong growth in CAG business and raised 2021 outlook.
Intuitive Surgical (ISRG) Hits 52-Week High: What's Behind It?
by Zacks Equity Research
Investors are optimistic about Intuitive Surgical's (ISRG) strength in its da Vinci surgical system.
LabCorp (LH) Inks Deal to Assess Disparities in Drug Development
by Zacks Equity Research
LabCorp (LH) and CCORN partner to develop a patient registry and biobank to help design cancer clinical trials in diverse populations.
Abiomed's (ABMD) Impella ECP Gets FDA's Breakthrough Device Tag
by Zacks Equity Research
Abiomed's (ABMD) Impella ECP is likely to offer critical hemodynamic support to a wider pool of coronary artery disease patients.
Here's Why You Should Retain Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies (COO) continues to benefit from strength in its business segments.
Edwards Lifesciences (EW) at a 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Edwards Lifesciences (EW) on strong sales growth across all four product groups in the second quarter and raised 2021 guidance.
ResMed's (RMD) AirSense 11 to Boost Sleep Apnea Digitalization
by Zacks Equity Research
ResMed's (RMD) new launch will make therapy setup easier for patients and help clinicians offer care more efficiently.